Compare Neurocrine Biosciences Inc (NBIX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs VF Corp — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while VF Corp trades at $16.88 (market cap $6.62B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.6× VF Corp's market cap, and VF Corp pays a 2.13% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | VFC | |
|---|---|---|
Market Cap | $17.40B | $6.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $21.55 |
52-Week Low | $123.10 | $11.66 |
Enterprise Value | $16.49B | $10.77B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
